CO2017003955A2 - Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos - Google Patents

Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos

Info

Publication number
CO2017003955A2
CO2017003955A2 CONC2017/0003955A CO2017003955A CO2017003955A2 CO 2017003955 A2 CO2017003955 A2 CO 2017003955A2 CO 2017003955 A CO2017003955 A CO 2017003955A CO 2017003955 A2 CO2017003955 A2 CO 2017003955A2
Authority
CO
Colombia
Prior art keywords
compounds
dihydropyridin
oxo
alkyl
present
Prior art date
Application number
CONC2017/0003955A
Other languages
English (en)
Inventor
Martin Hemmerling
Lena Elisabeth Ripa
Karolina Lawitz
Matti Juhani Lepistö
Karl Edman
Antonio Llinas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54252264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017003955(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO2017003955A2 publication Critical patent/CO2017003955A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere en forma general a los compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo (incluyendo sales de los mismos). La presente invención asimismo se refiere a las composiciones farmacéuticas y a los kits que comprenden dichos compuestos, a los usos de dichos compuestos (incluyendo métodos de tratamiento y preparación de medicamentos), y a los procesos para preparar dichos compuestos.
CONC2017/0003955A 2014-09-26 2017-04-24 Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos CO2017003955A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462055822P 2014-09-26 2014-09-26
PCT/EP2015/071862 WO2016046260A1 (en) 2014-09-26 2015-09-23 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators

Publications (1)

Publication Number Publication Date
CO2017003955A2 true CO2017003955A2 (es) 2017-05-10

Family

ID=54252264

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0003955A CO2017003955A2 (es) 2014-09-26 2017-04-24 Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos

Country Status (30)

Country Link
US (1) US10196374B2 (es)
EP (1) EP3197878B1 (es)
JP (1) JP6430000B2 (es)
KR (1) KR101866706B1 (es)
CN (1) CN107001320B (es)
AP (1) AP2017009819A0 (es)
AR (1) AR105549A1 (es)
AU (1) AU2015323817B2 (es)
BR (1) BR112017006085B1 (es)
CA (1) CA2962312C (es)
CL (1) CL2017000715A1 (es)
CO (1) CO2017003955A2 (es)
CR (1) CR20170106A (es)
DO (1) DOP2017000064A (es)
EA (1) EA031945B1 (es)
ES (1) ES2751640T3 (es)
GT (1) GT201700058A (es)
IL (1) IL250886A0 (es)
MX (1) MX2017003697A (es)
NI (1) NI201700038A (es)
NZ (1) NZ730250A (es)
PE (1) PE20171110A1 (es)
PH (1) PH12017500533A1 (es)
SG (1) SG11201702225VA (es)
SV (1) SV2017005412A (es)
TN (1) TN2017000096A1 (es)
TW (1) TW201619146A (es)
UY (1) UY36327A (es)
WO (1) WO2016046260A1 (es)
ZA (1) ZA201702720B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161518A1 (en) * 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
TW201927769A (zh) 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ii
MX2020006348A (es) 2017-12-18 2020-09-03 Gruenenthal Gmbh Pirrolidinamidas i sustituidas.
JP7446316B2 (ja) 2019-01-11 2024-03-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換ピロリジンアミドiii
EP3986886A2 (en) 2019-06-19 2022-04-27 Grünenthal GmbH Substituted pyrrolidine amides v
EP3986885B1 (en) 2019-06-19 2023-05-03 Grünenthal GmbH Substituted pyrrolidine amides iv
WO2021136429A1 (zh) * 2019-12-31 2021-07-08 南京明德新药研发有限公司 苯并吡唑类化合物
WO2022008705A1 (en) 2020-07-09 2022-01-13 Grünenthal GmbH Substituted pyrrolidine amines and amides as mediator of the glucocortoid receptor
WO2022012456A1 (en) * 2020-07-17 2022-01-20 Chengdu Easton Biopharmaceuticals Co., Ltd. Novel heterocyclic compounds as bet inhibitors
WO2023041695A1 (en) 2021-09-20 2023-03-23 Astrazeneca Ab Methods of treating inflammatory diseases with a selective glucocorticoid receptor modulator

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008506669A (ja) * 2004-07-16 2008-03-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 神経変性疾患の処置に適するピペリジン、ピペラジンもしくはモルホリンの二量体化合物またはそれらの7−員同族体
JO2754B1 (en) * 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
US20100080786A1 (en) * 2008-05-20 2010-04-01 Markus Berger Phenyl or Pyridinyl Substituted Indazoles Derivatives

Also Published As

Publication number Publication date
CA2962312C (en) 2019-01-15
CR20170106A (es) 2017-09-01
ES2751640T3 (es) 2020-04-01
BR112017006085A2 (pt) 2017-12-19
EA201790496A1 (ru) 2018-03-30
MX2017003697A (es) 2017-06-26
EP3197878A1 (en) 2017-08-02
AP2017009819A0 (en) 2017-03-31
CN107001320A (zh) 2017-08-01
NZ730250A (en) 2018-03-23
TW201619146A (zh) 2016-06-01
IL250886A0 (en) 2017-04-30
EA031945B1 (ru) 2019-03-29
US20170298041A1 (en) 2017-10-19
US10196374B2 (en) 2019-02-05
CN107001320B (zh) 2019-09-20
NI201700038A (es) 2018-01-05
PH12017500533A1 (en) 2017-08-07
BR112017006085B1 (pt) 2023-03-07
KR20170042785A (ko) 2017-04-19
AU2015323817B2 (en) 2018-11-01
UY36327A (es) 2016-04-01
KR101866706B1 (ko) 2018-06-11
CA2962312A1 (en) 2016-03-31
WO2016046260A8 (en) 2017-04-13
WO2016046260A1 (en) 2016-03-31
ZA201702720B (en) 2019-06-26
DOP2017000064A (es) 2017-03-31
TN2017000096A1 (en) 2018-07-04
PE20171110A1 (es) 2017-08-07
JP6430000B2 (ja) 2018-11-28
JP2017529369A (ja) 2017-10-05
CL2017000715A1 (es) 2017-11-10
EP3197878B1 (en) 2019-07-24
SV2017005412A (es) 2017-10-23
GT201700058A (es) 2019-08-12
SG11201702225VA (en) 2017-04-27
AR105549A1 (es) 2017-10-18
AU2015323817A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
CO2017003955A2 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
CO2017006214A2 (es) Derivados de quinazolina utilizados para tratar el vih
NI201600115A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112018073384A2 (pt) polinucleotídeos moduladores
CO2017001884A2 (es) Polimorfos de selinexor
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
EA201691582A1 (ru) Новые фармацевтические препараты
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
ECSP16074478A (es) Compuestos novedosos
CO2017000950A2 (es) Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos
GT201600250A (es) Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer
BR112017009471A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
CR20170157A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial
CL2016002267A1 (es) Ureas asimétricas p-sustituidas y usos médicos de las mismas